The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help. The interviews webpage also uses YouTube, where subtitles and translations are generated automatically by AI; please be advised to exercise caution when precise interpretation is required. For further support with YouTube, visit YouTube Help.
Does race affect treatment outcome in acute myeloid leukemia?
Ann-Kathrin Eisfeld
January 6, 2021
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, Know AML spoke to Ann-Kathrin Eisfeld, OSUCCC – The James, Columbus, US, about the impact of race on treatment outcome in acute myeloid leukemia. Results from a recent study on patients treated over three decades in the US indicate that African-American patients do poorly compared with white patients diagnosed with leukemia. Eisfeld explains the possible reasons for the different outcomes.
You can find additional patient journey resources via our interactive graphic page.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.
